Because there is a solid pharmacological rationale based on positive interactions between
long‐acting muscarinic receptor antagonists (LAMAs) and long‐acting β‐agonists (LABAs) …

Introduction To date, there is solid evidence from randomized controlled trials (RCTs)
supporting the rationale for withdrawal from inhaled corticosteroids (ICSs) in most patients …

The airway epithelium stretches and relaxes during the normal respiratory cycle, and
hyperventilation exaggerates this effect, resulting in changes in lung physiology. In fact …

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity
and mortality globally. In the major revision of the Global Initiative for Chronic Obstructive …

Background Bronchodilators are the cornerstone for treating patients with chronic
obstructive pulmonary diseases (COPD), although some studies have shown that dual …

Introduction Long-acting muscarinic receptor antagonist (LAMA)/β2-agonist (LABA)
combinations represent a significant improvement in the treatment of chronic obstructive …

Purpose: To evaluate the feasibility and success of a pharmacist-led, targeted inhaled
corticosteroid (ICS) de-escalation process in patients with chronic obstructive pulmonary …

La base del tratamiento de mantenimiento de la EPOC son los broncodilatadores de acción
larga y los corticoides inhalados. Frente a las modificaciones recientes en las guías de …

Despite available therapies for chronic obstructive pulmonary disease (COPD), significant
unmet treatment needs remain because most patients with COPD experience chronic …

Background Many chronic obstructive pulmonary disease (COPD) patients receiving
monotherapy continue to experience symptoms, exacerbations and poor quality of life. This …